{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"no emesis or rescue therapy; Acute complete response defined as no emesis or rescue therapy required from time point of 0 to 24 hours following melphalan therapy administration","groups":[{"description":"aprepitant plus standard anti-emetic regimen\n\no Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1: Add aprepitant to anti-emetic regimen","id":"OG000","title":"Aprepitant"},{"description":"olanzapine plus standard anti-emetic regimen\n\nOlanzapine10 mg orally daily on Days -1,0,+1 and +2: add olanzapine to anti-emetic regimen","id":"OG001","title":"Olanzapine"},{"description":"aprepitant and olanzapine plus standard anti-emetic regimen\n\nAprepitant plus Olanzapine: add aprepitant and olanzapine to anti-emetic regimen","id":"OG002","title":"Aprepitant Plus Olanzapine"}],"populationDescription":"No data were collected or analyzed for this outcome.","reportingStatus":"POSTED","timeFrame":"0 (transplant time) to 24 hours post-transplant","title":"Acute Complete Response","type":"SECONDARY"}